VISION: oVercoming Immunotherapy reSistance In cOlorectal caNcer

Colorectal cancer (CRC) ranks as the third leading cause of cancer-related mortality globally. Particularly, myeloid immune cells impede the efficacy of immunotherapy essential for eradicating cancer cells. We address this challenge by characterizing these myeloid cell subsets through imaging mass cytometry of CRC tumors and identifying therapeutic targets on these cells. Subsequently, we assess whether the blockade of these targets using antibodies can neutralize the suppressive function of myeloid cells. This approach holds the potential to render immunotherapy effective in treating this disease, paving the way for the future cure of more CRC patients.

Contact 
Iria López Estrada